Financial reports
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
4 Aug 21
10-Q
2021 Q1
Quarterly report
12 May 21
10-K
2020 FY
Annual report
10 Mar 21
10-Q
2020 Q3
Quarterly report
4 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
12 Mar 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
Current reports
8-K
Entry into a Material Definitive Agreement
19 Nov 21
8-K
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
12 Oct 21
8-K
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results
4 Aug 21
8-K
Departure of Directors or Certain Officers
12 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
25 Jun 21
8-K
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
12 May 21
8-K
Regulation FD Disclosure
11 May 21
8-K
Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
13 Apr 21
8-K
Departure of Directors or Certain Officers
5 Apr 21
8-K
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results
10 Mar 21
Registration and prospectus
15-12B
Securities registration termination
29 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 18
DEFA14A
Additional proxy soliciting materials
26 Apr 18
DEF 14A
Definitive proxy
28 Apr 17
DEFA14A
Additional proxy soliciting materials
28 Apr 17
Other
EFFECT
Notice of effectiveness
26 Nov 21
EFFECT
Notice of effectiveness
21 Sep 20
CORRESP
Correspondence with SEC
16 Sep 20
UPLOAD
Letter from SEC
16 Sep 20
CT ORDER
Confidential treatment order
12 Jul 19
CT ORDER
Confidential treatment order
4 Oct 18
EFFECT
Notice of effectiveness
13 Jul 17
CORRESP
Correspondence with SEC
12 Jul 17
UPLOAD
Letter from SEC
7 Jul 17
CT ORDER
Confidential treatment order
18 Apr 17
Ownership
SC 13G
Newtyn Management, LLC
24 Nov 21
4
Change in insider ownership
23 Nov 21
3
Initial statement of insider ownership
23 Nov 21
4
Mark Stejbach
19 Nov 21
4
ALAN MILINAZZO
19 Nov 21
4
C ANN MERRIFIELD
19 Nov 21
4
Heath Lukatch
19 Nov 21
4
Elizabeth Kwo
19 Nov 21
4
Utpal Koppikar
19 Nov 21
4
SAMUEL D COLELLA
19 Nov 21